Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights

Akebia to host conference call on March 9 at 8:30 a.m. ET Receives positive CHMP opinion for Vafseoâ„¢ (vadadustat); anticipates potential Marketing Authorization in Europe in May 2023 Reports Auryxia® (ferric citrate) net product revenue of $177.1M for 2022, an increase of approximately 24….